Degenerative Mitral Valve Disease

Degenerative mitral valve disease is the most prevalent acquired cardiac condition in dogs, accounting for approximately 75 percent of all canine heart disease cases seen in veterinary practice. The condition involves a progressive deterioration of the mitral valve, which separates the left atrium from the left ventricle. As the valve degenerates, it loses its ability to form a proper seal during ventricular contraction, allowing blood to flow backward into the left atrium in a process known as mitral regurgitation.

The mitral valve is composed of two leaflets anchored by chordae tendineae, which are thin fibrous cords connecting the valve leaflets to papillary muscles within the left ventricle. In a healthy heart, these structures work in concert to ensure unidirectional blood flow during each cardiac cycle. When degenerative changes occur, the valve leaflets become thickened, nodular, and progressively distorted, compromising their ability to coapt properly during systole.

The disease process is characterized by myxomatous degeneration, in which the normal layered structure of the valve leaflets is disrupted by an accumulation of glycosaminoglycans and proteoglycans within the valve tissue. This infiltration weakens the collagen framework and causes the leaflets to become redundant and floppy. Over time, the chordae tendineae may also undergo similar degenerative changes, becoming elongated or even rupturing, which further worsens valve incompetence.

Degenerative mitral valve disease is overwhelmingly a condition of older, small-breed dogs, although it can occur in any breed. The prevalence increases sharply with age, with some studies suggesting that nearly all Cavalier King Charles Spaniels over ten years of age have some degree of mitral valve degeneration detectable on echocardiography. While many affected dogs remain asymptomatic for years, the progressive nature of the disease means that a significant proportion will eventually develop clinical signs of congestive heart failure.

The precise etiology of degenerative mitral valve disease remains incompletely understood, but it is widely regarded as a multifactorial condition with strong genetic underpinnings. Research has consistently demonstrated that certain breeds are predisposed to developing the disease at younger ages and with greater severity, suggesting a heritable component to the valve degeneration process. In Cavalier King Charles Spaniels, the genetic basis is particularly well documented, with studies identifying polygenic inheritance patterns that influence the age of onset and rate of progression.

Age is the single most significant risk factor for developing degenerative mitral valve disease. The condition is rarely diagnosed in dogs younger than five years, except in highly predisposed breeds like the Cavalier King Charles Spaniel. By the time small-breed dogs reach ten to twelve years of age, the majority will have at least some degree of mitral valve degeneration. The age-related nature of the disease suggests that cumulative mechanical stress on the valve apparatus contributes to the degenerative process over the course of a dog's lifetime.

Body size plays an important role in disease susceptibility, with small and toy breed dogs being disproportionately affected compared to large and giant breeds. Dogs weighing less than twenty kilograms account for the vast majority of cases. However, when large-breed dogs do develop mitral valve disease, they tend to progress to heart failure more rapidly and carry a worse prognosis. Male dogs are also affected more frequently and tend to develop more severe disease than females of the same breed and age.

Serotonin signaling pathways have been implicated in the pathogenesis of myxomatous valve degeneration. Research has shown that valvular interstitial cells in affected dogs express altered serotonin receptor profiles, which may contribute to the aberrant extracellular matrix remodeling characteristic of the disease. Additionally, endothelial dysfunction, transforming growth factor beta signaling abnormalities, and mechanical shear stress have all been identified as potential contributors to the degenerative cascade.

Degenerative mitral valve disease follows a well-characterized progression that has been formalized into a staging system by the American College of Veterinary Internal Medicine. This consensus staging system provides a framework for guiding treatment decisions and is divided into four main stages, designated A through D. Understanding these stages is essential for appropriate management of affected dogs at each phase of the disease.

Stage A encompasses dogs that are at high risk of developing mitral valve disease but have no current structural abnormalities or cardiac murmur. This includes breeds with known predisposition, such as Cavalier King Charles Spaniels, where screening echocardiography may be recommended even in the absence of clinical findings. No treatment is indicated at this stage, but awareness and monitoring are emphasized to enable early detection when degenerative changes first appear.

Stage B is subdivided into B1 and B2 and includes dogs with a detectable heart murmur and confirmed mitral valve degeneration but no clinical signs of heart failure. Stage B1 dogs have mild to moderate regurgitation without significant cardiac remodeling, meaning the heart chambers remain normal in size on imaging. Stage B2 dogs have progressed to the point where the volume overload from chronic regurgitation has caused measurable enlargement of the left atrium and left ventricle. The distinction between B1 and B2 is clinically critical because landmark clinical trials have demonstrated that initiating pimobendan therapy at stage B2 significantly delays the onset of congestive heart failure.

Stage C represents dogs that have developed clinical signs of congestive heart failure, including cough, increased respiratory rate, exercise intolerance, and in some cases pulmonary edema. This stage requires aggressive medical management with multiple drug classes. Stage D designates dogs with end-stage, refractory congestive heart failure that no longer responds adequately to standard medical therapy. These patients require intensified treatment protocols and carry a guarded to poor prognosis despite intervention.

The clinical presentation of degenerative mitral valve disease varies considerably depending on the stage of the disease and the degree of hemodynamic compromise. In the early stages, many dogs are completely asymptomatic, and the only detectable abnormality is a systolic heart murmur heard best over the left apex of the chest. This murmur is caused by the turbulent blood flow created by mitral regurgitation and is often first identified during a routine veterinary examination. The intensity of the murmur generally correlates with the severity of regurgitation, though this relationship is not always precise.

As the disease progresses and the volume of regurgitant blood increases, the left atrium gradually dilates to accommodate the extra volume. When the left atrium enlarges sufficiently, it can compress the left mainstem bronchus, triggering a dry, hacking cough that is often more pronounced at night or during periods of excitement. This cough is frequently one of the earliest clinical signs noticed by owners and may initially be mistaken for a respiratory condition rather than a cardiac problem.

The onset of congestive heart failure marks a significant turning point in the clinical course. As the left side of the heart fails to manage the volume overload, pressure backs up into the pulmonary veins, leading to pulmonary edema. Dogs in heart failure typically exhibit increased respiratory rate and effort, orthopnea, reluctance to lie down, exercise intolerance, and episodes of restlessness, particularly at night. Some dogs may also develop a soft, moist cough productive of frothy fluid, which indicates fluid accumulation in the airways.

In advanced cases, right-sided heart failure may develop secondary to chronic left-sided disease, resulting in ascites, jugular venous distension, and peripheral edema. Additional signs can include syncope or collapse episodes caused by cardiac arrhythmias or acute drops in cardiac output, weight loss and muscle wasting from cardiac cachexia, and decreased appetite. Acute decompensation can also occur following chordal rupture, where sudden worsening of regurgitation causes fulminant pulmonary edema requiring emergency stabilization.

Diagnosis of degenerative mitral valve disease begins with a thorough physical examination, during which the hallmark finding is a systolic heart murmur with the point of maximal intensity over the left cardiac apex. The murmur is typically graded on a scale of one through six, with higher grades generally reflecting more significant regurgitation. Auscultation alone, however, is insufficient to determine the stage of disease or guide treatment decisions, making additional diagnostic testing essential for comprehensive evaluation.

Thoracic radiography is a fundamental component of the diagnostic workup and serves multiple purposes. Radiographs allow assessment of cardiac silhouette size, with enlargement of the left atrium and left ventricle indicating significant volume overload. The vertebral heart score, a standardized measurement comparing heart size to thoracic vertebral length, provides an objective and reproducible metric for tracking cardiac enlargement over time. Radiographs are also critical for identifying pulmonary edema, pulmonary venous congestion, and other complications that indicate the onset of congestive heart failure.

Echocardiography is the gold standard diagnostic modality for evaluating degenerative mitral valve disease and is essential for accurate staging. Two-dimensional echocardiography reveals the characteristic thickening, prolapse, and distortion of the mitral valve leaflets. M-mode measurements provide quantitative data on chamber dimensions, including left atrial to aortic root ratio and left ventricular internal diameter in diastole, both of which are key parameters for distinguishing stage B1 from B2 disease. Color flow Doppler imaging directly visualizes the regurgitant jet and allows semiquantitative assessment of its severity.

Additional diagnostic tools include electrocardiography, which may reveal sinus tachycardia, atrial premature complexes, or atrial fibrillation in advanced cases. Cardiac biomarkers such as cardiac troponin I and N-terminal pro-B-type natriuretic peptide can provide supplementary information about myocardial injury and volume overload, respectively. Blood pressure measurement is also important, as systemic hypertension can exacerbate mitral regurgitation, and hypotension may indicate severely compromised cardiac output in end-stage disease.

The treatment approach for degenerative mitral valve disease is stage-dependent and has been significantly informed by several landmark veterinary clinical trials. No treatment is recommended for stage A or stage B1 dogs, as there is currently no evidence that any medication delays disease progression in these early phases. Monitoring with periodic echocardiography and radiography is advised to detect progression to stage B2, at which point therapeutic intervention becomes beneficial.

The EPIC trial, published in 2016, demonstrated that initiating pimobendan in preclinical stage B2 dogs significantly prolonged the time to onset of congestive heart failure by a median of approximately fifteen months. Pimobendan is an inodilator that enhances cardiac contractility through calcium sensitization while also producing vasodilation through phosphodiesterase III inhibition. Based on this evidence, pimobendan has become the standard of care for stage B2 dogs meeting specific echocardiographic criteria for cardiac enlargement.

Once congestive heart failure develops at stage C, a multimodal pharmacological approach is required. The standard triple therapy consists of furosemide to reduce fluid overload, pimobendan to support cardiac function, and an angiotensin-converting enzyme inhibitor such as enalapril or benazepril to counteract neurohormonal activation. Furosemide dosing is titrated to the lowest effective dose that controls clinical signs while minimizing the risk of dehydration and electrolyte imbalances. Spironolactone may be added as an aldosterone antagonist to provide additional neurohormonal blockade and mild diuretic effect.

Stage D patients with refractory heart failure require escalated therapy, which may include increasing furosemide doses, adding additional diuretics such as hydrochlorothiazide, initiating antiarrhythmic medications if significant arrhythmias are present, and considering afterload reduction with amlodipine or hydralazine. Dietary sodium restriction and omega-3 fatty acid supplementation may provide supportive benefit. Close monitoring of renal values, electrolytes, respiratory rate, and body weight is essential for ongoing management of these complex patients.

Mitral valve repair surgery has emerged as a potentially curative treatment option for dogs with degenerative mitral valve disease, offering the possibility of eliminating or dramatically reducing mitral regurgitation rather than simply managing the consequences medically. The procedure involves open-heart surgery performed under cardiopulmonary bypass, during which the surgeon repairs the damaged valve leaflets, replaces ruptured or elongated chordae tendineae with artificial sutures, and reduces the dilated mitral annulus to restore proper valve geometry.

The surgical technique most commonly employed is modeled after procedures developed in human cardiac surgery and has been refined for veterinary application primarily in Japan, France, the United Kingdom, and the United States. The operation requires a highly specialized team including a veterinary cardiac surgeon, perfusionist, anesthesiologist, and dedicated nursing staff. Success rates at experienced centers have been reported above ninety percent for survival to discharge, with many dogs achieving near-complete resolution of mitral regurgitation and reversal of cardiac remodeling in the months following surgery.

Despite the promising outcomes, mitral valve repair surgery remains limited in availability and carries significant considerations. The procedure is technically demanding and requires substantial infrastructure, including a cardiopulmonary bypass circuit, specialized surgical instrumentation, and an intensive care unit capable of managing complex postoperative cardiac patients. The financial cost is considerable, typically ranging from tens of thousands of dollars, which places it out of reach for many dog owners. Patient selection is also critical, as dogs with severe myocardial dysfunction, significant comorbidities, or very advanced heart failure may not be ideal surgical candidates.

For owners considering surgery, the timing of intervention is important. Dogs that undergo repair before severe myocardial damage has occurred tend to have the best outcomes, with significant improvement in cardiac function and quality of life. Research continues to expand the accessibility and refine the techniques of mitral valve surgery in dogs, and as more centers develop the capacity to perform the procedure, it is likely to become an increasingly viable option for appropriate candidates.

Ongoing monitoring is a cornerstone of managing degenerative mitral valve disease at every stage. For preclinical dogs in stages B1 and B2, periodic veterinary reassessment with auscultation, echocardiography, and thoracic radiography is recommended to track disease progression and determine optimal timing for initiating or adjusting therapy. The frequency of monitoring varies with the stage and rate of progression but typically ranges from every six to twelve months for stable B1 dogs to every four to six months for B2 dogs on pimobendan.

Resting respiratory rate monitoring at home is one of the most valuable tools available to owners for the early detection of congestive heart failure. Owners are instructed to count the number of breaths their dog takes per minute while sleeping or resting calmly, recording these values daily or several times per week. A consistent resting respiratory rate below thirty breaths per minute is generally considered normal, while a sustained increase above this threshold may indicate the development or worsening of pulmonary edema and warrants prompt veterinary evaluation.

Dietary management plays a supportive role in the overall care plan. Moderate sodium restriction is generally recommended for dogs in heart failure, though extreme sodium restriction is unnecessary and may reduce palatability at a time when maintaining caloric intake is important. Ensuring adequate protein intake is essential to counteract the muscle wasting associated with cardiac cachexia. Omega-3 fatty acid supplementation from marine sources has been suggested to provide anti-inflammatory and anti-cachectic benefits, though the evidence in veterinary patients remains limited.

Exercise recommendations should be tailored to the individual dog's stage of disease and functional capacity. Preclinical dogs can generally maintain their normal activity levels without restriction. Dogs in compensated heart failure benefit from continued mild to moderate activity, as complete inactivity can accelerate deconditioning and muscle loss. However, strenuous exercise and activity in extreme heat or humidity should be avoided, as these conditions place additional demands on an already compromised cardiovascular system.

The prognosis for degenerative mitral valve disease is highly variable and depends on numerous factors including the stage at diagnosis, rate of progression, breed, body size, and response to therapy. Many dogs with preclinical disease live for years without developing clinical signs, and some will ultimately die of unrelated causes before heart failure ever manifests. The natural history of the disease is one of gradual progression, but the rate at which individual dogs advance through the stages can differ dramatically.

For dogs that progress to stage B2 and are started on pimobendan, the available evidence suggests a meaningful delay in the onset of heart failure compared to untreated dogs. The EPIC trial demonstrated a median time to heart failure or cardiac death of approximately 1228 days in the pimobendan group versus 766 days in the placebo group, representing a substantial clinical benefit. This underscores the importance of early detection and appropriate staging to identify dogs that will benefit from preemptive therapy.

Once congestive heart failure develops, survival times with medical management are more limited but still meaningful. Studies have reported median survival times ranging from approximately nine to eighteen months after the first episode of heart failure, depending on the study population and treatment protocols employed. Dogs that respond well to initial stabilization and whose heart failure is effectively managed with standard triple therapy tend to have longer survival times than those who are refractory to treatment or who present with severe decompensation.

Factors associated with a poorer prognosis include large left atrial size, the presence of atrial fibrillation, chordal rupture, pulmonary hypertension, concurrent renal disease, and the development of right-sided heart failure. Conversely, dogs that maintain a good appetite, stable body weight, and low resting respiratory rates on therapy tend to fare better. For dogs that undergo successful mitral valve repair surgery, the prognosis can be excellent, with many achieving near-normal cardiac function and life expectancy.

The Cavalier King Charles Spaniel occupies a unique position in the context of degenerative mitral valve disease, as the breed is affected earlier, more frequently, and often more severely than any other breed. Studies have shown that approximately fifty percent of Cavalier King Charles Spaniels develop a mitral murmur by five years of age, and virtually all individuals are affected by ten years. This extraordinary prevalence has prompted breed-specific screening programs in many countries, where breeding stock is evaluated by echocardiography and auscultation to reduce the propagation of early-onset disease.

Other small breeds with notable predisposition include the Dachshund, Miniature and Toy Poodle, Chihuahua, Maltese, Yorkshire Terrier, Pomeranian, and Cocker Spaniel. In these breeds, the onset of mitral valve disease typically occurs later than in the Cavalier King Charles Spaniel, with most dogs developing detectable murmurs after seven to eight years of age. The disease pattern in these breeds generally follows the classic course of gradual progression from mild regurgitation to eventual heart failure over a period of years.

Large and giant breed dogs can develop degenerative mitral valve disease, though it is far less common than in small breeds. When large-breed dogs are affected, the presentation may differ in important ways. These dogs tend to have more rapid progression from preclinical disease to heart failure, and the volume overload created by mitral regurgitation in a larger heart can lead to more dramatic cardiac remodeling. Atrial fibrillation is also more common in large-breed dogs with advanced mitral valve disease, which can further compromise cardiac function and complicate management.

Breeding recommendations for predisposed breeds emphasize cardiac screening prior to breeding, ideally by a board-certified veterinary cardiologist. Various breeding protocols have been proposed, generally recommending that dogs should not be bred until they have been cleared of murmurs at a specified age, with both parents and ideally grandparents also being free of early-onset disease. While these programs cannot eliminate the disease entirely due to its polygenic nature, they represent the best available strategy for reducing the prevalence and severity of degenerative mitral valve disease in future generations.